Related Experiment Videos
Decrease of rapid-eye-movement sleep in the light by intraventricular application of a VIP-antagonist in the rat.
M Mirmiran1, J Kruisbrink, N P Bos
1Netherlands Institute for Brain Research, Amsterdam.
Brain Research
|August 16, 1988
Summary
Vasoactive intestinal polypeptide (VIP) promotes REM sleep. A VIP antagonist significantly reduced REM sleep duration in rats, suggesting VIP
Area of Science:
- Neuroscience
- Sleep Science
- Pharmacology
Background:
- Vasoactive intestinal polypeptide (VIP) is known to increase rapid-eye-movement (REM) sleep in animal models.
- Understanding the precise role of VIP in sleep regulation is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the effect of a novel VIP antagonist on sleep-wake patterns in male rats.
- To determine if VIP plays a role in the generation and maintenance of REM sleep.
Main Methods:
- Continuous intracerebroventricular administration of a competitive VIP antagonist ([4Cl-D-Phe6-Leu17]-VIP).
- Monitoring of sleep-wake patterns in male rats over a 24-hour light-dark cycle.
Main Results:
- The VIP antagonist significantly reduced the time spent in REM sleep by 44% during the light phase.
- No significant effects were observed during the dark phase (data not shown).
Conclusions:
- VIP appears to play a significant role in the generation and maintenance of REM sleep.
- Pharmacological antagonism of VIP disrupts normal REM sleep patterns.